CA Patent

CA2995923C — Methods to treat opioid use disorder

Assigned to Indivior UK Ltd · Expires 2023-03-21 · 3y expired

What this patent protects

The disclosure provides buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder, to reduce or eliminate opioid withdrawal symptoms, to reduce or eliminate opioid craving, and to induce and maintain …

USPTO Abstract

The disclosure provides buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder, to reduce or eliminate opioid withdrawal symptoms, to reduce or eliminate opioid craving, and to induce and maintain opioid abstinence.

Drugs covered by this patent

Patent Metadata

Patent number
CA2995923C
Jurisdiction
CA
Classification
—
Expires
2023-03-21
Drug substance claim
No
Drug product claim
No
Assignee
Indivior UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.